Palynziq™ (pegvaliase-pqpz) – New drug approval
May 24, 2018 - The FDA announced the approval of BioMarin’s Palynziq™ (pegvaliase-pqpz), to reduce blood phenylalanine (Phe) concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood Phe concentrations greater than 600 micromol/L on existing management.
Top